Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR exon 20 insertion
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
Guardant360® CDx (54)
FoundationOne® Liquid CDx (20)
Oncomine™ Dx Target Test (10)
Guardant360® CDx (54)
FoundationOne® Liquid CDx (20)
Oncomine™ Dx Target Test (10)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: A1 - Approval
GlobeNewswire - 4 weeks (New A1)
amivantamab-vmjw
Sensitive
:
A1
GlobeNewswire - 4wk
amivantamab-vmjw
Sensitive: A1 - Approval
GlobeNewswire - 4 weeks
amivantamab-vmjw
Sensitive
:
A1
GlobeNewswire - 4 weeks - (New A1)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive: A1 - Approval
mobocertinib
Sensitive
:
A1
mobocertinib
Sensitive: A1 - Approval
mobocertinib
Sensitive
:
A1
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
DZD9008
Sensitive: A1 - Approval
DZD9008
Sensitive
:
A1
DZD9008
Sensitive: A1 - Approval
DZD9008
Sensitive
:
A1
EGFR exon 20 insertion
Lung Non-Squamous Non-Small Cell Cancer
EGFR exon 20 insertion
Lung Non-Squamous Non-Small Cell Cancer
amivantamab-vmjw
Sensitive: A2 - Guideline
amivantamab-vmjw
Sensitive
:
A2
amivantamab-vmjw
Sensitive: A2 - Guideline
amivantamab-vmjw
Sensitive
:
A2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
CLN-081
Sensitive: B - Late Trials
CLN-081
Sensitive
:
B
CLN-081
Sensitive: B - Late Trials
CLN-081
Sensitive
:
B
EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR exon 20 insertion
Lung Non-Squamous Non-Small Cell Cancer
EGFR exon 20 insertion
Lung Non-Squamous Non-Small Cell Cancer
firmonertinib
Sensitive: B - Late Trials
firmonertinib
Sensitive
:
B
firmonertinib
Sensitive: B - Late Trials
firmonertinib
Sensitive
:
B
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
cetuximab + afatinib
Sensitive: C2 – Inclusion Criteria
cetuximab + afatinib
Sensitive
:
C2
cetuximab + afatinib
Sensitive: C2 – Inclusion Criteria
cetuximab + afatinib
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
osimertinib
Sensitive: C2 – Inclusion Criteria
osimertinib
Sensitive
:
C2
osimertinib
Sensitive: C2 – Inclusion Criteria
osimertinib
Sensitive
:
C2
EGFR exon 20 insertion
Solid Tumor
EGFR exon 20 insertion
Solid Tumor
BDTX-189
Sensitive: C2 – Inclusion Criteria
BDTX-189
Sensitive
:
C2
BDTX-189
Sensitive: C2 – Inclusion Criteria
BDTX-189
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
poziotinib
Sensitive: C2 – Inclusion Criteria
poziotinib
Sensitive
:
C2
poziotinib
Sensitive: C2 – Inclusion Criteria
poziotinib
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
firmonertinib
Sensitive: C2 – Inclusion Criteria
firmonertinib
Sensitive
:
C2
firmonertinib
Sensitive: C2 – Inclusion Criteria
firmonertinib
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + osimertinib
Sensitive
:
C2
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + osimertinib
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
aumolertinib
Sensitive: C2 – Inclusion Criteria
aumolertinib
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
PH001
Sensitive: C2 – Inclusion Criteria
PH001
Sensitive
:
C2
PH001
Sensitive: C2 – Inclusion Criteria
PH001
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: C3 – Early Trials
cisplatin + pemetrexed
Sensitive
:
C3
cisplatin + pemetrexed
Sensitive: C3 – Early Trials
cisplatin + pemetrexed
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR inhibitor
Resistant
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
gefitinib
Resistant: C3 – Early Trials
gefitinib
Resistant
:
C3
gefitinib
Resistant: C3 – Early Trials
gefitinib
Resistant
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
erlotinib
Resistant: C3 – Early Trials
erlotinib
Resistant
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
Platinum alkylating agent
Sensitive: C3 – Early Trials
Platinum alkylating agent
Sensitive
:
C3
Platinum alkylating agent
Sensitive: C3 – Early Trials
Platinum alkylating agent
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
KN046
Sensitive: C3 – Early Trials
KN046
Sensitive
:
C3
KN046
Sensitive: C3 – Early Trials
KN046
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
anlotinib + sintilimab
Sensitive: C3 – Early Trials
anlotinib + sintilimab
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
Angiogenesis inhibitor
Sensitive: C3 – Early Trials
Angiogenesis inhibitor
Sensitive
:
C3
Angiogenesis inhibitor
Sensitive: C3 – Early Trials
Angiogenesis inhibitor
Sensitive
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
EGFR exon 20 insertion
Lung Adenocarcinoma
EGFR exon 20 insertion
Lung Adenocarcinoma
afatinib
Resistant: C3 – Early Trials
afatinib
Resistant
:
C3
afatinib
Resistant: C3 – Early Trials
afatinib
Resistant
:
C3
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login